Page last updated: 2024-08-21

erythromycin and 7432 s

erythromycin has been researched along with 7432 s in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bale, MJ; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA1
Cellesi, C; Chigiotti, S; Corbisiero, R; Mencarelli, M; Rossolini, GM; Zanchi, A1
Simon, MW1

Reviews

1 review(s) available for erythromycin and 7432 s

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for erythromycin and 7432 s

ArticleYear
Treatment of acute sinusitis in childhood with ceftibuten.
    Clinical pediatrics, 1999, Volume: 38, Issue:5

    Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Ceftibuten; Cephalosporins; Child; Child, Preschool; Erythromycin; Female; Humans; Infant; Male; Sinusitis; Sulfisoxazole

1999

Other Studies

4 other study(ies) available for erythromycin and 7432 s

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
    Journal of clinical microbiology, 1992, Volume: 30, Issue:1

    Topics: Anti-Bacterial Agents; Cefdinir; Cefpirome; Ceftibuten; Ceftizoxime; Cephalosporins; Clarithromycin; Erythromycin; Fleroxacin; Fluoroquinolones; Haemophilus; Humans; Microbial Sensitivity Tests; Quality Control; Quinolones; Spectinomycin; Virginiamycin

1992
Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:3

    Topics: Anti-Bacterial Agents; Azithromycin; beta-Lactam Resistance; Ceftibuten; Ceftriaxone; Cephalosporins; Chi-Square Distribution; Erythromycin; Humans; Italy; Microbial Sensitivity Tests; Penicillin G; Streptococcus pyogenes

1996